Colorectal cancer (CRC) is the third most common malignancy worldwide, and the second leading cause of cancer-associated mortality. The incidence and mortality rates of CRC remain high, posing a significant threat to humans and overall quality of life. Current therapeutic strategies, such as surgery and chemotherapy, are limited due to disease recurrence, chemotherapeutic drug resistance and toxicity. Thus, research is focused on the development of novel treatment approaches. In 2012, ferroptosis was identified as a form of regulated cell death that is iron-dependent and driven by lipid peroxidation. Notably, therapies targeting ferroptosis exhibit potential in the treatment of disease; however, their role in CRC treatment remains controversial. The present study aimed to systematically review the mechanisms and signaling pathways of ferroptosis in CRC, and the specific role within the tumor microenvironment. Moreover, the present study aimed to review the role of ferroptosis in drug resistance, offering novel perspectives for the diagnosis and treatment of CRC.
colorectal cancerferroptosistumor microenvironmentdrug resistancemechanism of actionsignaling pathwayShandong Province's Traditional Chinese Medicine Science and Technology Development Project2019-0187Qilu Chinese Medicine Advantageous Specialty Cluster Construction ProjectYWC2022ZKJQ0003This article is funded by Shandong Province's Traditional Chinese Medicine Science and Technology Development Project (grant no. 2019-0187) and Qilu Chinese Medicine Advantageous Specialty Cluster Construction Project (grant no. YWC2022ZKJQ0003).Introduction
Colorectal cancer (CRC) is a prevalent malignancy of the gastrointestinal tract, with high rates of morbidity and mortality. In 2018, the GLOBOCAN database published an analysis of the incidence and mortality rates for 36 cancers across 185 countries, and the results revealed that CRC is the third most common cancer and the second leading cause of cancer-associated mortalities worldwide (1,2). The etiology of CRC is associated with various factors, including age, sex, inflammatory bowel disease, lifestyle and environmental factors (3–5). Current treatment options for CRC include surgery, chemotherapy, radiotherapy, immunotherapy and targeted biological therapies (6). However, the absence of highly specific biomarkers for the diagnosis of CRC and the development of chemoresistance in advanced stages of treatment may impact the quality of life of patients with late-stage disease (7). Thus, research is focused on the development of novel effective targeted therapies for CRC. Notably, ferroptosis may exhibit potential as an emerging strategy for CRC treatment.
Regulated cell death, including apoptosis, pyroptosis, necroptosis, ferroptosis, autophagy-dependent cell death and neoplastic cell death, is a crucial mechanism for maintaining the internal homeostasis of the human body and preserving tissue function and morphology (8,9). The primary method for distinguishing between different forms of cell death is based on the associated morphological characteristics (Table I).
Ferroptosis, initially described by Dixon in 2012, is a novel form of regulated cell death (9). It is distinct from other forms of regulated cell death in terms of morphology, biochemical features and gene expression (10). Notably, ferroptosis is characterized by unique morphological features, including mitochondrial shrinkage, increased mitochondrial membrane density, reduced or absent mitochondrial cristae, rupture of the outer mitochondrial membrane, and preservation of nuclear integrity (11,12). The main morphological characteristics of apoptosis include cell shrinkage, nuclear condensation and the maintenance of plasma membrane integrity, while its biochemical features are primarily DNA fragmentation and macromolecule synthesis (13). The key morphological traits of pyroptosis involve cell swelling, the formation of numerous bubbles on the pyroptotic cells, and chromatin degradation, leading to the formation of inflammasomes (14–16). The primary morphological characteristics of necroptosis include increased cell membrane permeability, cell swelling and loss of organelle integrity, while its biochemical hallmark is a decrease in adenosine triphosphate levels (17,18). Autophagy is characterized by the formation of double-membraned autophagosomes, and its biochemical feature is an increase in lysosomal activity (19).
Ferroptosis has been investigated in a variety of diseases, including Parkinson's disease (20,21), Alzheimer's disease (22,23), liver injury (24,25), brain injury (26,27), spinal cord injury (28–30), kidney injury (31,32), cardiovascular disease (33–35) and gynecological disorders (36,37) (Fig. 1). At present, research is focused on the role of ferroptosis in the treatment of cancer. Yan et al (38) demonstrated that ferroptosis plays a key role in the development of CRC, breast cancer, ovarian cancer, renal cancer, lymphoma and melanoma (39). However, results of a previous study revealed that ferroptosis may also play a role in CRC progression and metastasis, through the activation of different signaling pathways (40). Thus, previous studies highlight that ferroptosis may exert contrasting effects in CRC, demonstrating the requirement for further investigations. In addition, the development of novel treatment approaches is required to mitigate the adverse effects of ferroptosis on CRC. This article systematically reviews the mechanisms and signaling pathways of ferroptosis in CRC, the role of ferroptosis within the tumor microenvironment, and the progress in research on ferroptosis in reducing drug resistance. It aims to provide new insights for the diagnosis and treatment of CRC.
Mechanism of action of ferroptosis
Ferroptosis is primarily characterized by the excessive accumulation of iron and lipid reactive oxygen species (10). Previous studies have identified mechanisms that may be involved with ferroptosis, including amino acid, lipid and iron metabolism (41). Key mechanisms involved in ferroptosis are displayed in Fig. 2.
Induction of ferroptosis through inhibition of the cystine/glutamate antiporter system (System Xc-)
System Xc- is a critical component of the cellular antioxidant system that is widely distributed in the phospholipid bilayer. System Xc- is a heterodimer composed of two subunits: Namely, solute carrier family 7 member 11 (SLC7A11) and SLC3A2. System Xc- facilitates the 1:1 exchange of cystine and glutamate across the cell membrane (9). Once inside the cell, cystine is utilized to synthesize glutathione, which, in the presence of glutathione peroxidase, reduces the production of lipid reactive oxygen species. Therefore, inhibition of System Xc- leads to reduced glutathione peroxidase activity, decreased cellular antioxidant capacity, accumulation of lipid reactive oxygen species and ferroptosis (9). A well-established oncogene, P53, may induce ferroptosis via downregulation of SLC7A11 expression, thereby inhibiting System Xc- activity (42,43). Moreover, sorafenib (44), sulfasalazine (45) and erastin (46) induce ferroptosis via inhibition of System Xc-.
Induction of ferroptosis through inhibition of glutathione peroxidase 4 (GPX4)
GPX4 plays a critical role in the cellular peroxidase system, inhibiting the formation of peroxides and thus acting as a key regulator of ferroptosis. GPX4 catalyzes the conversion of glutathione to oxidized glutathione and reduces cytotoxic lipid peroxides to their corresponding alcohols (12). Yang et al (47) demonstrated that reduced GPX4 expression may lead to the induction of ferroptosis, whereas increased GPX4 expression may inhibit ferroptosis. RAS-selective lethal 3 (RSL3) is a widely established inhibitor of GPX4 and an inducer of ferroptosis. RSL3 directly targets GPX4, thereby inhibiting its activity and leading to reductions in cellular antioxidant capacity, the accumulation of lipid reactive oxygen species and the induction of ferroptosis (48). Costa et al (49) identified ML162 and ML210 as GPX4 inhibitors that induce ferroptosis, through a mechanism that is comparable with that of RSL3.
Lipid metabolism
Lipid peroxidation is critical in the induction of ferroptosis. Lipids are essential components of cell membranes, and lipid peroxidation disrupts these membranes, thereby triggering ferroptosis (50). Polyunsaturated fatty acids (PUFAs), such as arachidonic acid and adrenic acid, are long-chain fatty acids with multiple double bonds that are highly susceptible to lipid peroxidation. Phosphatidylethanolamine containing arachidonic and adrenic acids is a key phospholipid in the induction of cellular ferroptosis. There are two lipid-metabolizing enzymes associated with ferroptosis; namely, acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3, which are involved in the biosynthesis of phosphatidylethanolamine. These enzymes activate PUFAs and impact their transmembrane properties, leading to ferroptosis (51). In addition, cytochrome P450 oxidoreductase-mediated lipid peroxidation may play a key role in the induction of ferroptosis (52). Cytochrome P450 oxidoreductase transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to oxygen, producing hydrogen peroxide. Hydrogen peroxide subsequently reacts with iron to generate reactive hydroxyl radicals, which peroxidize the polyunsaturated fatty acid chains of membrane phospholipids. This process disrupts the integrity of cellular membranes during iron accumulation, ultimately leading to ferroptosis (53,54).
Iron metabolism
Iron accumulation is closely associated with ferroptosis, and primarily involves iron absorption and reduction processes (55). Iron is a critical raw material for the production of hemoglobin and myoglobin. Moreover, iron plays a vital role in various cellular metabolic processes, such as oxygen storage and transport, DNA and RNA synthesis, cellular differentiation, and enzymatic reactions (56). Healthy individuals exhibit iron levels of 3–5 g, with >50% circulating in red blood cells as hemoglobin or stored as ferritin. In addition, small amounts of iron bind to transferrin in the plasma (57,58).
Intracellular iron homeostasis is maintained through a balance of iron absorption, utilization, storage and excretion. Fe3+ is absorbed in the duodenum and jejunum, and transported into cells via transferrin receptor 1, where it is reduced to Fe2+ by metal reductase in the endoplasmic reticulum. For biological activation, a small amount of Fe2+ is released into a labile iron pool in the cytoplasm via the divalent metal transporter 1, while the remainder is recycled or stored as ferritin (59,60). The results of a previous study revealed that cancer cells require higher levels of iron than healthy cells, and are more susceptible to iron depletion, also known as iron addiction (61). Notably, in the presence of a large number of cancer cells, ferritin is degraded through autophagy. This process is carried out via autophagy-related proteins 5 and 7, and the nuclear receptor coactivator 4 (NCOA4) signaling pathways. NCOA4 binds to lysosomes, degrades ferritin and releases Fe2+, leading to an abnormal increase in Fe2+ levels (62–64). Excessive Fe2+ accumulation triggers the Fenton reaction (Fig. 3), initiating ferroptosis and further contributing to the accumulation of reactive oxygen species (65).
Ferroptosis in CRC
At present, research is focused on the role of drug- (Table II), gene-, protein- (Table III), and RNA-induced ferroptosis (Table IV). Each of these mechanisms play distinct roles in CRC.
Drug-induced ferroptosis
In 2021, Yang et al (66) reported that cetuximab inhibits the progression of KRAS-mutant CRC through the promotion of RSL3-induced ferroptosis via inhibition of the Nrf2/heme oxygenase 1 (HO-1) signaling pathway. Results of a previous study demonstrated that apatinib promotes ferroptosis in CRC cells via the ELOVL6/ACSL4 signaling pathway, highlighting the potential role of ferroptosis in CRC treatment (67). Ibrutinib enhances the sensitivity of CRC cells to ferroptosis through the BTK/nRF2 signaling pathway, thereby inhibiting CRC progression (68). In addition, Zhao et al (69) demonstrated that propofol induces ferroptosis in CRC cells via downregulation of STAT3 expression. The results of a previous study revealed that aspirin promotes RSL3-induced ferroptosis through inhibition of the mTOR/SREBP-1/SCD1 signaling pathway, highlighting the potential role of ferroptosis in the treatment of PIK3CA-mutant CRC (70).
In addition, herbs and plant extracts may induce ferroptosis. Emodin, a natural anthraquinone derivative extracted from various herbs, may induce ferroptosis in CRC cells through NCOA4-mediated ferritin autophagy and NF-κB pathways, thereby inhibiting CRC progression (71). Ginsenoside Rh3, a semi-natural product isolated from Panax ginseng, may induce ferroptosis in CRC cells via the Stat3/p53/NRF2 axis, demonstrating potential in the treatment of cancer (72). Moreover, curcumin may inhibit CRC through the induction of ferroptosis. Results of a previous study demonstrated that curcumin played a role in the regulation of oncogenes, such as P53, and the SLC7A11/glutathione/GPX4 axis (73). The combination of curcumin and Andrographis paniculata may induce ferroptosis in CRC, through the downregulation of GPX4 and iron regulatory protein 1 (74). In addition, esculin induces endoplasmic reticulum stress through the regulation of eukaryotic translation initiation factor 2α/CHOP and Nrf2/HO-1 pathways via the PERK signaling pathway; thus, promoting apoptosis and ferroptosis in CRC cells, ultimately inhibiting CRC occurrence and progression (75). Results of a previous study revealed that baicalein promotes ferroptosis through inhibition of the JAK2/STAT3/GPX4 signaling pathway; thus, exerting an inhibitory effect on CRC (76).
Gene- and protein-induced ferroptosis
Kruppel-like factor 2 (KLF2) is an oncogene that may also inhibit CRC progression. Notably, KLF2 suppresses the PI3K/AKT signaling pathway, thereby inducing ferroptosis (77). Results of a previous study demonstrated that bromelain inhibits the proliferation of KRAS-mutant CRC cells and induces ferroptosis via ACSL4 (78). Wei et al (79) revealed that Tagitinin C, a novel inducer of ferroptosis, acts as a potent chemosensitizer that enhances the efficacy of chemotherapeutic agents. Notably, Tagitinin C induces ferroptosis through the PERK/Nrf2/HO-1 signaling pathway. TIGAR, a TP53-induced regulator of glycolysis and apoptosis, plays a crucial role in energy metabolism, autophagy, stem cell differentiation and cell survival (80). Liu et al (81) demonstrated that TIGAR inhibits CRC progression through increasing the sensitivity of CRC cells to ferroptosis via the ROS/AMPK/SCD1 signaling pathway. Chaudhary et al (82) revealed that lipid carrier protein 2 inhibits ferroptosis through upregulation of GPX4 expression and the cystine/glutamate antiporter component, xCT; thus, promoting CRC progression. Moreover, increased expression of lipid carrier protein 2 may lead to resistance to 5-fluorouracil in CRC cells, further contributing to chemotherapeutic resistance. In a recent study, it has been reported that TRIM36-mediated FOXA2 promotes colorectal cancer by inhibiting the Nrf2/GPX4 signaling pathway and suppressing ferroptosis. However, the specific mechanism by which FOXA2 regulates Nrf2, whether directly or indirectly, remains unclear (83). Results of a previous study demonstrated that uridine-cytidine kinase-like 1 (UCKL1) enhances the proliferation and metastasis of CRC cells via the UCKL1/Nrf2/SLC7A11 axis, ultimately inhibiting ferroptosis and promoting CRC development and progression (84). These findings suggest that reduced lipid carrier protein 2, FOXA2 and UCKL1 expression levels may promote ferroptosis; thus, acting as an effective strategy for the treatment of CRC.
RNA-regulated ferroptosis
MicroRNAs (miRNAs/miRs) may play a role in the regulation of ferroptosis. Results of a previous study have revealed that miR-148a-3p acts as a tumor suppressor in CRC through targeting SLC7A11 and activating ferroptosis (85). In addition, miR-509-5p promotes ferroptosis through targeting SLC7A1 (86), while miR-15a-3p induces ferroptosis through the direct targeting of GPX4 (87). The oncogenic miRNA, miR-19a, promotes the proliferation, migration and invasion of CRC cells. Iron-responsive element binding protein 2 (IREB2) is a direct target of miR-19a. Thus, targeting IREB2 may lead to the inhibition of ferroptosis via miR-19a, exhibiting potential as a novel target for CRC treatment (88). In addition, results of a previous study have revealed that miR-545 suppresses transferrin, promoting CRC cell survival through the inhibition of ferroptosis (89).
Long non-coding RNAs (lncRNAs) may also regulate ferroptosis. The results of a previous study have revealed that LINC00239 may act as a ferroptosis inhibitor in CRC, through interaction with Kelch-like ECH-associated protein 1. This leads to a reduction in the antitumor activity of Erastin and RSL3, and the promotion of CRC progression (90).
Ferroptosis and the tumor microenvironment (TME)
Ferroptotic damage induces the activation of immune responses within the TME (45). Thus, further investigations into the interaction between ferroptosis and the TME may provide a basis for the development of effective strategies for CRC treatment (91).
The TME is a complex environment containing tumor cells, stromal cells, immune cells, adipocytes, endothelial cells and the extracellular matrix (92). Dai et al (93) revealed that autophagic degradation-mediated ferroptosis leads to the release of cancer cell components into the TME and tumor-associated macrophage polarization. Moreover, Ma et al (94) revealed that CD36 mediates fatty acid uptake via CD8+ T cells within the TME induced ferroptosis, leading to a reduction in CD8+ T cell effector function and antitumor activity. In addition, cancer-associated fibroblasts in the TME may impair the antitumor capacity of natural killer cells through the induction of ferroptosis (95).
Notably, CD8+ T cells resist tumor growth and metastasis via multiple mechanisms (96–98). The results of a previous study have demonstrated that CD8+ T cell-derived IFN-γ promotes ferroptosis in cancer cells. This process leads to the release of a variety of tumor antigens into the TME, and antigen-presenting cell-mediated activation of CD8+ T cells, thereby enhancing anticancer immunity. However, CD8+ T cells in tumors exhibit increased levels of sensitivity to ferroptosis compared with cancer cells, which may limit the use of ferroptosis inducers in the treatment of cancer (99).
Inducing ferroptosis may attenuate drug resistance in CRCMitigating CRC-associated drug resistance to chemotherapy
Chemotherapy is the most common post-operative treatment for patients with CRC. The results of our previous study demonstrated that oxaliplatin and 5-fluorouracil are highly associated with ferroptosis in CRC (82,100) (Table V).
The results of a previous study revealed that the induction of ferroptosis through the inhibition of the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway enhances sensitivity to oxaliplatin, thereby improving the quality of life of patients with CRC (100). In addition, inhibition of cysteine desulfurase expression leads to increased intracellular reactive oxygen species levels, the promotion of ferroptosis and reduced levels of resistance to oxaliplatin (101). Overexpression of RNA-binding motif single-stranded interacting protein 1 (RBMS1) inhibits ferroptosis; therefore, suppressing RBMS1 expression may increase the sensitivity of CRC cells to oxaliplatin (102). Inhibition of Candida nucleata also promotes ferroptosis and decreases CRC cell resistance to oxaliplatin (103). The results of a previous study also demonstrated that oxaliplatin resistance is reversed following inhibition of cyclin-dependent kinase 1 expression (104).
Overexpression of lipid transport protein 2 leads to inhibition of ferroptosis, which ultimately increases the resistance to 5-fluorouracil. Therefore, targeting lipid transport protein 2 levels may attenuate resistance to 5-fluorouracil (82). In addition, serine protease 1 is associated with chemotherapeutic resistance in CRC. This protein is highly expressed in CRC cells and is negatively associated with the prognosis of patients. Moreover, Liu et al (105) demonstrated that serine protease 1 interacts with SLC7A11 to increase expression levels, ultimately inhibiting ferroptosis, leading to increased resistance to 5-fluorouracil. Thus, targeting serine protease 1 may exhibit potential in the treatment of CRC.
Mitigating CRC-associated drug resistance to targeted therapies
When targeting cancer cells, chemotherapy may also target healthy cells. Thus, targeted therapy is considered an alternative treatment option to chemotherapy. Mu et al (106) demonstrated that 3-bromopyruvic acid and cetuximab may induce ferroptosis; thus, exhibiting potential in mitigating cetuximab resistance in CRC. In addition, the combination of β-elemene, a natural product derived from turmeric, and cetuximab may exert effects on metastatic CRC cells with Kras mutations, inducing ferroptosis and reducing cetuximab resistance (107).
Conclusions
At present, research is focused on the role of ferroptosis in the physiological and pathological processes of numerous diseases, leading to the development of novel treatment approaches. The present study aimed to review the specific mechanisms underlying ferroptosis in CRC, including drug-, gene-, protein- and RNA-induced ferroptosis. The aforementioned forms of ferroptosis play distinct roles in CRC. For example, various signaling pathways directly facilitate drug-induced ferroptosis, thereby impeding CRC onset and progression. By contrast, gene-, protein- and RNA-induced ferroptosis involve specific signaling pathways and mechanisms that may exhibit potential as effective strategies for targeted CRC treatment. Notably, mechanisms may include targeting of GPX4 expression and xCT, the Nrf2/GPX4 signaling pathway, the UCKL1/Nrf2/SLC7A11 signaling pathway, miR-19a, miR-545, and lncRNA LINC00239. In addition, the association between ferroptosis and the TME further highlighted that induction of ferroptosis may attenuate drug resistance in CRC.
Results of the present study demonstrated that induction of ferroptosis may inhibit CRC progression. In addition, genes, proteins and RNAs that inhibit ferroptosis may promote CRC development and progression. However, the clinical application of ferroptosis is limited at present, as the specific mechanisms and signaling pathways through which ferroptosis promotes or inhibits CRC development are yet to be fully elucidated. Thus, further investigations into the specific role of ferroptosis in CRC are required for the development of effective targeted therapies.
In conclusion, ferroptosis may exhibit potential in the treatment of CRC. Further investigations are required to elucidate the signaling pathways involved in ferroptosis, and to identify the genes, proteins and signaling pathways that inhibit ferroptosis in CRC. Moreover, further investigations should focus on determining alternative therapeutic modalities that may increase the therapeutic effects of ferroptosis, and on assessing the specific anti-tumor effects of ferroptosis in CRC progression. An increased understanding of ferroptosis in CRC may lead to the effective implementation of treatment in clinical practice.
Acknowledgements
The figures were created using Figdraw.
Availability of data and materials
Not applicable.
Authors' contributions
ZG, HZ and XS contributed to the conception and the main idea of the work. ZG and HZ drafted the manuscript, figures and tables. XS reviewed and modified the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Ethics approval and consent to participate
Not applicable.
Competing interests
All authors declare that they have no competing interests.
ReferencesFavoritiPCarboneGGrecoMPirozziFPirozziRECorcioneFWorldwide burden of colorectal cancer: A reviewUpdates Surg68711201610.1007/s13304-016-0359-y27067591BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin68394424201810.3322/caac.2149230207593BouvardVLoomisDGuytonKZGrosseYGhissassiFEBenbrahim-TallaaLGuhaNMattockHStraifKInternational Agency for Research on Cancer Monograph Working GroupCarcinogenicity of consumption of red and processed meatLancet Oncol1615991600201510.1016/S1470-2045(15)00444-126514947JohnsonCHDejeaCMEdlerDHoangLTSantidrianAFFeldingBHIvanisevicJChoKWickECHechenbleiknerEMMetabolism links bacterial biofilms and colon carcinogenesisCell Metab21891897201510.1016/j.cmet.2015.04.01125959674DejeaCMWickECHechenbleiknerEMWhiteJRMark WelchJLRossettiBJPetersonSNSnesrudECBorisyGGLazarevMMicrobiota organization is a distinct feature of proximal colorectal cancersProc Natl Acad Sci USA1111832118326201410.1073/pnas.140619911125489084BensonABVenookAPAl-HawaryMMCederquistLChenYJCiomborKKCohenSCooperHSDemingDEngstromPFNCCN guidelines insights: Colon cancer, version 2.2018J Natl Compr Canc Netw16359369201810.6004/jnccn.2018.002129632055GuoJXuBHanQZhouHXiaYGongCDaiXLiZWuGFerroptosis: A novel Anti-tumor action for cisplatinCancer Res Treat50445460201810.4143/crt.2016.57228494534StockwellBRFriedmann AngeliJPBayirHBushAIConradMDixonSJFuldaSGascónSHatziosSKKaganVEFerroptosis: A regulated cell death nexus linking metabolism, redox biology, and diseaseCell171273285201710.1016/j.cell.2017.09.02128985560DixonSJLembergKMLamprechtMRSkoutaRZaitsevEMGleasonCEPatelDNBauerAJCantleyAMYangWSFerroptosis: An iron-dependent form of nonapoptotic cell deathCell14910601072201210.1016/j.cell.2012.03.04222632970XuSHeYLinLChenPChenMZhangSThe emerging role of ferroptosis in intestinal diseaseCell Death Dis12289202110.1038/s41419-021-03559-133731703YagodaNvon RechenbergMZaganjorEBauerAJYangWSFridmanDJWolpawAJSmuksteIPeltierJMBonifaceJJRAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channelsNature447865869200710.1038/nature05859LiJCaoFYinHLHuangZJLinZTMaoNSunBWangGFerroptosis: Past, present and futureCell Death Dis1188202010.1038/s41419-020-2298-232015325Ketelut-CarneiroNFitzgeraldKAApoptosis, pyroptosis, and Necroptosis-oh my! The many ways a cell can dieJ Mol Biol434167378202210.1016/j.jmb.2021.16737834838807AgliettiRADueberECRecent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functionsTrends Immunol38261271201710.1016/j.it.2017.01.00328196749FangYTianSPanYLiWWangQTangYYuTWuXShiYMaPShuYPyroptosis: A new frontier in cancerBiomed Pharmacother121109595202010.1016/j.biopha.2019.10959531710896LiuXZhangZRuanJPanYMagupalliVGWuHLiebermanJInflammasome-activated gasdermin D causes pyroptosis by forming membrane poresNature535153158201610.1038/nature1862927383986SunLWangHWangZHeSChenSLiaoDWangLYanJLiuWLeiXWangXMixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinaseCell148213227201210.1016/j.cell.2011.11.03122265413NegroniAColantoniECucchiaraSStronatiLNecroptosis in intestinal inflammation and cancer: New concepts and therapeutic perspectivesBiomolecules101431202010.3390/biom1010143133050394LiuSYaoSYangHLiuSWangYAutophagy: Regulator of cell deathCell Death Dis14648202310.1038/s41419-023-06154-837794028GuineySJAdlardPABushAIFinkelsteinDIAytonSFerroptosis and cell death mechanisms in Parkinson's diseaseNeurochem Int1043448201710.1016/j.neuint.2017.01.00428082232Do VanBGouelFJonneauxATimmermanKGeléPPétraultMBastideMLalouxCMoreauCBordetRFerroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKCNeurobiol Dis94169178201610.1016/j.nbd.2016.05.01127189756YanNZhangJIron metabolism, ferroptosis, and the links with Alzheimer's diseaseFront Neurosci131443202010.3389/fnins.2019.0144332063824CongLDongXWangYDengYLiBDaiROn the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's diseaseEur J Med Chem1661121201910.1016/j.ejmech.2019.01.03930684867DengGLiYMaSGaoZZengTChenLYeHYangMShiHYaoXCaveolin-1 dictates ferroptosis in the execution of acute immune-mediated hepatic damage by attenuating nitrogen stressFree Radic Biol Med148151161202010.1016/j.freeradbiomed.2019.12.02631877357ParkSJChoSSKimKMYangJHKimJHJeongEHYangJWHanCYKuSKChoIJKiSHProtective effect of sestrin2 against iron overload and ferroptosis-induced liver injuryToxicol Appl Pharmacol379114665201910.1016/j.taap.2019.11466531323261ZhangZWuYYuanSZhangPZhangJLiHLiXShenHWangZChenGGlutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhageBrain Res1701112125201810.1016/j.brainres.2018.09.01230205109KennyEMFidanEYangQAnthonymuthuTSNewLAMeyerEAWangHKochanekPMDixonCEKaganVEBayirHFerroptosis contributes to neuronal death and functional outcome after traumatic brain injuryCrit Care Med47410418201910.1097/CCM.000000000000355530531185YaoXZhangYHaoJDuanHQZhaoCXSunCLiBFanBYWangXLiWXDeferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosisNeural Regen Res14532201910.4103/1673-5374.24548030539824ZhangYSunCZhaoCHaoJZhangYFanBLiBDuanHLiuCKongXFerroptosis inhibitor SRS 16–86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injuryBrain Res17064857201910.1016/j.brainres.2018.10.02330352209ShiZYuanSShiLLiJNingGKongXFengSProgrammed cell death in spinal cord injury pathogenesis and therapyCell Prolif54e12992202110.1111/cpr.1299233506613Martin-SanchezDRuiz-AndresOPovedaJCarrascoSCannata-OrtizPSanchez-NiñoMDRuiz OrtegaMEgidoJLinkermannAOrtizASanzABFerroptosis, but not necroptosis, is important in nephrotoxic folic Acid-induced AKIJ Am Soc Nephrol28218229201710.1681/ASN.201512137627352622MüllerTDewitzCSchmitzJSchröderASBräsenJHStockwellBRMurphyJMKunzendorfUKrautwaldSNecroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failureCell Mol Life Sci7436313645201710.1007/s00018-017-2547-428551825LiuBZhaoCLiHChenXDingYXuSPuerarin protects against heart failure induced by pressure overload through mitigation of ferroptosisBiochem Biophys Res Commun497233240201810.1016/j.bbrc.2018.02.06129427658ChenXXuSZhaoCLiuBRole of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failureBiochem Biophys Res Commun5163743201910.1016/j.bbrc.2019.06.01531196626LiDPiWSunZLiuXJiangJFerroptosis and its role in cardiomyopathyBiomed Pharmacother153113279202210.1016/j.biopha.2022.11327935738177NgSWNorwitzSGNorwitzERThe impact of iron overload and ferroptosis on reproductive disorders in humans: Implications for preeclampsiaInt J Mol Sci203283201910.3390/ijms2013328331277367NgSWNorwitzSGTaylorHSNorwitzEREndometriosis: The role of iron overload and ferroptosisReprod Sci2713831390202010.1007/s43032-020-00164-z32077077YanHFZouTTuoQZXuSLiHBelaidiAALeiPFerroptosis: Mechanisms and links with diseasesSignal Transduct TargetTher649202110.1038/s41392-020-00428-9YanHTaltyRAladelokunOBosenbergMJohnsonCHFerroptosis in colorectal cancer: A future target?Br J Cancer12814391451202310.1038/s41416-023-02149-636703079WuTWanJQuXXiaKWangFZhangZYangMWuXGaoRYuanXNodal promotes colorectal cancer survival and metastasis through regulating SCD1-mediated ferroptosis resistanceCell Death Dis14229202310.1038/s41419-023-05756-637002201WangYZhangZSunWZhangJXuQZhouXMaoLFerroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targetsBiomed Pharmacother153113524202210.1016/j.biopha.2022.11352436076606JiangLHickmanJHWangSJGuWDynamic roles of p53-mediated metabolic activities in ROS-induced stress responsesCell Cycle1428812885201510.1080/15384101.2015.106847926218928JiangLKonNLiTWangSJSuTHibshooshHBaerRGuWFerroptosis as a p53-mediated activity during tumour suppressionNature5205762201510.1038/nature1434425799988LiQChenKZhangTJiangDChenLJiangJZhangCLiSUnderstanding Sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapyEur J Pharmacol955175913202310.1016/j.ejphar.2023.17591337460053ChenXKangRKroemerGTangDBroadening horizons: The role of ferroptosis in cancerNat Rev Clin Oncol18280296202110.1038/s41571-020-00462-033514910WangLLiuYDuTYangHLeiLGuoMDingHFZhangJWangHChenXYanCATF3 promotes Erastin-induced ferroptosis by suppressing system XcCell Death Differ27662675202010.1038/s41418-019-0380-z31273299YangWSStockwellBRSynthetic lethal screening identifies compounds activating Iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cellsChem Biol15234245200810.1016/j.chembiol.2008.02.01018355723SuiXZhangRLiuSDuanTZhaiLZhangMHanXXiangYHuangXLinHXieTRSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancerFront Pharmacol91371201810.3389/fphar.2018.0137130524291CostaIBarbosaDJBenfeitoSSilvaVChavarriaDBorgesFRemiãoFSilvaRMolecular mechanisms of ferroptosis and their involvement in brain diseasesPharmacol Ther244108373202310.1016/j.pharmthera.2023.10837336894028HarayamaTRiezmanHUnderstanding the diversity of membrane lipid compositionNat Rev Mol Cell Biol19281296201810.1038/nrm.2017.13829410529KaganVEMaoGQuFAngeliJPDollSCroixCSDarHHLiuBTyurinVARitovVBOxidized arachidonic and adrenic PEs navigate cells to ferroptosisNat Chem Biol138190201710.1038/nchembio.223827842066KoppulaPZhuangLGanBCytochrome P450 reductase (POR) as a ferroptosis fuelProtein Cell12675679202110.1007/s13238-021-00823-033539003YanBAiYSunQMaYCaoYWangJZhangZWangXMembrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1Mol Cell81355369.e10202110.1016/j.molcel.2020.11.02433321093ZouYLiHGrahamETDeikAAEatonJKWangWSandoval-GomezGClishCBDoenchJGSchreiberSLCytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosisNat Chem Biol16302309202010.1038/s41589-020-0472-632080622NingXQiHYuanYLiRWangYLinZYinYIdentification of a new small molecule that initiates ferroptosis in cancer cells by inhibiting the system Xc− to deplete GSHEur J Pharmacol934175304202210.1016/j.ejphar.2022.17530436174666FanXLiAYanZGengXLianLLvHGaoDZhangJFrom iron metabolism to ferroptosis: Pathologic changes in coronary heart diseaseOxid Med Cell Longev20226291889202210.1155/2022/629188935993022ZhouLZhaoBZhangLWangSDongDLvHShangPAlterations in cellular iron metabolism provide more therapeutic opportunities for cancerInt J Mol Sci191545201810.3390/ijms1905154529789480BasakTKanwarRKIron imbalance in cancer: Intersection of deficiency and overloadCancer Med1138373853202210.1002/cam4.476135460205ChifmanJLaubenbacherRTortiSVA systems biology approach to iron metabolismAdv Exp Med Biol844201225201410.1007/978-1-4939-2095-2_1025480643HanCLiuYDaiRIsmailNSuWLiBFerroptosis and its potential role in human diseasesFront Pharmacol11239202010.3389/fphar.2020.0023932256352ManzDHBlanchetteNLPaulBTTortiFMTortiSVIron and cancer: Recent insightsAnn N Y Acad Sci1368149161201610.1111/nyas.1300826890363ZhouBLiuJKangRKlionskyDJKroemerGTangDFerroptosis is a type of Autophagy-dependent cell deathSemin Cancer Biol6689100202010.1016/j.semcancer.2019.03.00230880243ManciasJDWangXGygiSPHarperJWKimmelmanACQuantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagyNature509105109201410.1038/nature1314824695223HouWXieYSongXSunXLotzeMTZehHJIIIKangRTangDAutophagy promotes ferroptosis by degradation of ferritinAutophagy1214251428201610.1080/15548627.2016.118736627245739XieYHouWSongXYuYHuangJSunXKangRTangDFerroptosis: Process and functionCell Death Differ23369379201610.1038/cdd.2015.15826794443YangJMoJDaiJYeCCenWZhengXJiangLYeLCetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancerCell Death Dis121079202110.1038/s41419-021-04367-334775496TianXLISGeGApatinib promotes ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4 SignalingCancer Manag Res1313331342202110.2147/CMAR.S27463133603479ZhuJFLiuYLiWTLiMHZhenCHSunPWChenJXWuWHZengWIbrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathwayCell Death Dis14151202310.1038/s41420-023-01449-336823108ZhaoXChenFPropofol induces the ferroptosis of colorectal cancer cells by downregulating STAT3 expressionOncol Lett22767202110.3892/ol.2021.1302834589146ChenHQiQWuNWangYFengQJinRJiangLAspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancerRedox Biol55102426202210.1016/j.redox.2022.10242635963119ShenZZhaoLYooSALinZZhangYYangWPiaoJEmodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-κb pathway inactivationApoptosisMay52024doi: 10.1007/s10495-024-01973-2 (Epub ahead of print)10.1007/s10495-024-01973-2WuYPiDZhouSYiZDongYWangWYeHChenYZuoQOuyangMGinsenoside Rh3 induces pyroptosis and ferroptosis through the Stat3/p53/NRF2 axis in colorectal cancer cellsActa Biochim Biophys Sin (Shanghai)55587600202310.3724/abbs.202306837092860MingTLeiJPengYWangMLiangYTangSTaoQWangMTangXHeZCurcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53 and solute carrier family 7 member 11/glutathione/glutathione peroxidase 4 signaling axisPhytother Res3839543972202410.1002/ptr.825838837315MiyazakiKXuCShimadaMGoelACurcumin and andrographis exhibit Anti-tumor effects in colorectal cancer via activation of ferroptosis and dual suppression of glutathione Peroxidase-4 and ferroptosis suppressor Protein-1Pharmaceuticals (Basel)16383202310.3390/ph1603038336986483JiXChenZLinWWuQWuYHongYTongHWangCZhangYEsculin induces endoplasmic reticulum stress and drives apoptosis and ferroptosis in colorectal cancer via PERK regulating eIF2α/CHOP and Nrf2/HO-1 cascadesJ Ethnopharmacol328118139202410.1016/j.jep.2024.11813938561058LaiJQZhaoLLHongCZouQMSuJXLiSJZhouXFLiZSDengBCaoJQiQBaicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axisActa Pharmacol Sin4517151726202410.1038/s41401-024-01258-z38684798LiJJiangJLChenYMLuWQKLF2 inhibits colorectal cancer progression and metastasis by inducing ferroptosis via the PI3K/AKT signaling pathwayJ Pathol Clin Res9423435202310.1002/cjp2.32537147883ParkSOhJKimMJinEJBromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosisAnim Cells Syst (Seoul)22334340201810.1080/19768354.2018.151252130460115WeiRZhaoYWangJYangXLiSWangYYangXFeiJHaoXZhaoYTagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cellsInt J Biol Sci1727032717202110.7150/ijbs.5940434345202KoYHDomingo-VidalMRocheMLinZWhitaker-MenezesDSeifertECapparelliCTulucMBirbeRCTassonePTP53-inducible glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancerJ Biol Chem2912629126303201610.1074/jbc.M116.74020927803158LiuMYLiHMWangXYXiaRLiXMaYJWangMZhangHSTIGAR drives colorectal cancer ferroptosis resistance through ROS/AMPK/SCD1 pathwayFree Radic Biol Med182219231202210.1016/j.freeradbiomed.2022.03.00235271998ChaudharyNChoudharyBSShahSGKhapareNDwivediNGaikwadAJoshiNRaichannaJBasuSGurjarMLipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancerInt J Cancer14914951511202110.1002/ijc.3371134146401LiuXYanCChangCMengFShenWWangSZhangYFOXA2 suppression by TRIM36 exerts Anti-tumor role in colorectal cancer via inducing NRF2/GPX4-Regulated ferroptosisAdv Sci (Weinh)10e2304521202310.1002/advs.20230452137875418WuWZhaoYQinBJiangXWangCHuRMaRLeeMHLiuHLiKYuanPNon-canonical role of UCKL1 on ferroptosis defence in colorectal cancerEBioMedicine93104650202310.1016/j.ebiom.2023.10465037343364MartinoEBalestrieriAAragonaFBifulcoGMeleLCampanileGBalestrieriMLD'OnofrioNMiR-148a-3p promotes colorectal cancer cell ferroptosis by targeting SLC7A11Cancers (Basel)154342202310.3390/cancers1517434237686618ElrebehyMAAbdelghanyTMElshafeyMMGomaaMHDoghishASmiR-509-5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11Pathol Res Pract247154557202310.1016/j.prp.2023.15455737229918LiuLYaoHZhouXChenJChenGShiXWuGZhouGHeSMiR-15a-3p regulates ferroptosis via targeting glutathione peroxidase GPX4 in colorectal cancerMol Carcinog61301310202210.1002/mc.2336734727409FanHAiRMuSNiuXGuoZLiuLMiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2Bioengineered131202112029202210.1080/21655979.2022.205419435599631ZhengSHuLSongQShanYYinGZhuHKongWZhouCmiR-545 promotes colorectal cancer by inhibiting transferring in the non-normal ferroptosis signalingAging132613726147202110.18632/aging.20380134954694HanYGaoXWuNJinYZhouHWangWLiuHChuYCaoJJiangMLong noncoding RNA LINC00239 inhibits ferroptosis in colorectal cancer by binding to Keap1 to stabilize Nrf2Cell Death Dis13742202210.1038/s41419-022-05192-y36038548BinnewiesMRobertsEWKerstenKChanVFearonDFMeradMCoussensLMGabrilovichDIOstrand-RosenbergSHedrickCCUnderstanding the tumor immune microenvironment (TIME) for effective therapyNat Med24541550201810.1038/s41591-018-0014-x29686425ChenFZhuangXLinLYuPWangYShiYHuGSunYNew horizons in tumor microenvironment biology: Challenges and opportunitiesBMC Med1345201510.1186/s12916-015-0278-725857315DaiEHanLLiuJXieYKroemerGKlionskyDJZehHJKangRWangJTangDAutophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS proteinAutophagy1620692083202010.1080/15548627.2020.171420931920150MaXXiaoLLiuLYeLSuPBiEWangQYangMQianJYiQCD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor abilityCell Metab3310011012.e5202110.1016/j.cmet.2021.02.01533691090YaoLHouJWuXLuYJinZYuZYuBLiJYangZLiCCancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulationRedox Biol67102923202310.1016/j.redox.2023.10292337832398St PaulMOhashiPSThe roles of CD8+ T cell subsets in antitumor immunityTrends Cell Biol30695704202010.1016/j.tcb.2020.06.00332624246TangRXuJZhangBLiuJLiangCHuaJMengQYuXShiSFerroptosis, necroptosis, and pyroptosis in anticancer immunityJ Hematol Oncol13110202010.1186/s13045-020-00946-732778143HanJKhatwaniNSearlesTGTurkMJAngelesCVMemory CD8+ T cell responses to cancerSemin Immunol49101435202010.1016/j.smim.2020.10143533272898LinZZouSWenKThe crosstalk of CD8+ T cells and ferroptosis in cancerFront Immunol141255443202410.3389/fimmu.2023.125544338288118YangCZhangYLinSLiuYLiWSuppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatinAging (Albany NY)131351513534202110.18632/aging.20277433819186LinJFHuPSWangYYTanYTYuKLiaoKWuQNLiTMengQLinJZPhosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosisSignal Transduct Target Ther754202210.1038/s41392-022-00889-035221331XuYHaoJChenQQinYQinHRenSSunCZhuYShaoBZhangJWangHInhibition of the RBMS1/PRNP axis improves ferroptosis resistance-mediated oxaliplatin chemoresistance in colorectal cancerMol Carcinog63224237202410.1002/mc.2364737861356LiBWeiZWangZXuFYangJLinBChenYWenrenHWuLGuoXFusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancerFree Radic Biol Med220125138202410.1016/j.freeradbiomed.2024.04.22638657754ZengKLiWWangYZhangZZhangLZhangWXingYZhouCInhibition of CDK1 Overcomes oxaliplatin resistance by regulating ACSL4-mediated ferroptosis in colorectal cancerAdv Sci (Weinh)102301088202310.1002/advs.20230108837428466LiuWLiuCXiaoJQianCChenZLinWZhangYWuJZhouRZhaoLHTRA1 interacts with SLC7A11 to modulate colorectal cancer chemosensitivity by inhibiting ferroptosisCell Death Discovery10228202410.1038/s41420-024-01993-638740771MuMZhangQZhaoCLiXChenZSunXYuJ3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing Autophagy-dependent ferroptosisCancer Gene Therapy3014141425202310.1038/s41417-023-00648-537558749ChenPLiXZhangRLiuSXiangYZhangMChenXPanTYanLFengJCombinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting Epithelial-mesenchymal transformationTheranostics1051075119202010.7150/thno.4470532308771
Ferroptosis is implicated in a wide range of diseases, including neurological, cardiac, cerebral, spinal cord, gastrointestinal, gynecological and hepatic disorders.
Regulatory mechanisms of ferroptosis. SLC7A11, solute carrier family 7 member 11; SLC3A2, solute carrier family 3 Member 2; System Xc-, cystine/glutamate antiporter system; GSH, glutathione; GSSG, oxidized glutathione; GPX4, glutathione peroxidase 4; PUFA, polyunsaturated fatty acid; ACSL4, acyl-CoA synthetase long-chain family member 4; LPCAT3, lysophosphatidylcholine acyltransferase 3; TFR1, transferrin receptor 1; STEAP3, six transmembrane epithelial antigen of the prostate 3; DMT1, divalent metal transporter 1; NCOA4, nuclear receptor coactivator 4; ROS, reactive oxygen species.
Fenton reaction.
Characteristics of ferroptosis, apoptosis, pyroptosis, necroptosis and autophagy.
Regulated form of cell death
Morphological characteristic
Biochemical characteristic
(Refs.)
Ferroptosis
Decreased mitochondrial volume, reduced number of cristae, increased mitochondrial membrane density and elevated rates of mitochondrial membrane rupture
Iron accumulation and lipid peroxidation
(8)
Apoptosis
Cell shrinkage, nuclear condensation and preservation of cytoplasmic membrane integrity
DNA fragmentation and macromolecular synthesis
(13)
Pyroptosis
Cell swelling and expansion, formation of numerous vesicles in necrotic cells, chromatin degradation, and the release of pro-inflammatory components
Inflammatory vesicle formation
(14–16)
Necroptosis
Plasma membrane permeabilization, cellular swelling and loss of organelle integrity
Decreased levels of adenosine triphosphate
(17,18)
Autophagy
Formation of autophagic lysosomes with double-membrane structures
Increased lysosomal activity
(19)
Drug-induced ferroptosis may lead to inhibition of CRC development and progression.
Chemotherapeutic agent
Mechanism
(Refs.)
Cetuximab
Enhanced RSL3-induced ferroptosis through inhibition of the Nrf2/HO-1 signaling pathway
(66)
Apatinib
Promotion of ferroptosis through the ELOVL6/ACSL4 signaling pathway
(67)
Irrutinib
Enhanced sensitivity to ferroptosis in CRC cells via the BTK/nRF2 signaling pathway
(68)
Propofol
Downregulation of STAT3 expression
(69)
Aspirin
Enhanced RSL3-induced ferroptosis through inhibition of the mTOR/SREBP-1/SCD1 signaling pathway
(70)
Emodin
Induction of ferroptosis in CRC cells via NCOA4-mediated ferritin autophagy and the NF-κb pathway
(71)
Ginsenoside Rh3
Induction of ferroptosis in CRC cells via the Stat3/p53/NRF2 axis
(72)
Curcumin
Promotion of ferroptosis through regulation of the oncogene, P53, and the SLC7A11/glutathione/GPX4 axis
(73)
Curcumin in combination with Andrographis paniculata
Promotion of ferroptosis through downregulation of GPX4 and iron regulatory protein 1 expression levels
(74)
Esculin
Induction of endoplasmic reticulum stress via apoptosis and ferroptosis, through regulation of eIF2α/CHOP and Nrf2/HO-1 via the PERK signaling pathway
(75)
Baicalein
Promotion of ferroptosis through inhibition of the JAK2/STAT3/GPX4 signaling pathway
(76)
RSL3, RAS-selective lethal 3; Nrf2, nuclear factor erythroid 2-related factor 2; ELOVL6, elongation of very long chain fatty acids protein 6; ACSL4, Acyl-CoA synthetase long-chain family member 4; STAT3, signal transducer and activator of transcription 3; mTOR, mechanistic target of rapamycin; SREBP-1, sterol regulatory element-binding protein 1; SCD1, stearoyl-CoA desaturase 1; NCOA4, Nuclear receptor coactivator 4; SLC7A11, solute carrier family 7 member 11; GPX4, glutathione peroxidase 4; PERK, protein kinase R-like endoplasmic reticulum kinase; JAK2, Janus kinase 2; CRC, colorectal cancer.
Gene- and protein-induced ferroptosis in CRC.
A, Inhibition of CRC development and progression
Gene or protein
Mechanism
(Refs.)
Kruppel-like factor 2
Induction of ferroptosis through inhibition of the PI3K/AKT signaling pathway
(77)
Bromelain
Inhibition of proliferation and induction of ferroptosis in KRAS-mutant CRC cells through ACSL4
(78)
Tagitinin C
Induction of ferroptosis through the PERK/Nrf2/HO-1 signaling pathway
(79)
TIGAR
Increased sensitivity of CRC cells to ferroptosis via the ROS/AMPK/SCD1 signaling pathway
(80,81)
B, Promotion of colorectal carcinogenesis and progression
Gene or protein
Mechanism
(Refs.)
Lipid transport protein 2
Induction of ferroptosis through increased expression of glutathione peroxidase 4 and the cystine/glutamate antiporter component, xCT
(82)
FOXA2
Inhibition of ferroptosis through inhibition of the Nrf2/GPX4 signaling pathway
(83)
Uridine cytidine kinase-like 1
Inhibition of ferroptosis through the UCKL1/Nrf2/SLC7A11 axis
(84)
PI3K, phosphoinositide 3-kinase; KRAS-mutant, Kirsten rat sarcoma viral oncogene homolog; ACSL4, acyl-CoA synthetase long-chain family member 4; ROS, reactive oxygen species; AMPK, AMP-activated protein kinase; SCD1, stearoyl-CoA desaturase 1; xCT, cystine/glutamate transporter; Nrf2, nuclear factor erythroid 2-related factor 2; GPX4, glutathione peroxidase 4; UCKL1, uridine-cytidine kinase-like 1; SLC7A11, solute carrier family 7 member 11; CRC, colorectal cancer.
RNA-regulated ferroptosis in CRC.
A, Inhibition of CRC development and progression
RNA
Mechanism
(Refs.)
miR-148a-3p
Activation of ferroptosis via targeting of SLC7A11
(85)
miR-509-5p
Promotion of ferroptosis via targeting of SLC7A1
(86)
miR-15a-3p
Activation of ferroptosis via direct targeting of GPX4
(87)
B, Promotion of colorectal carcinogenesis and progression
RNA
Mechanism
(Refs.)
miR-19a
Inhibition of ferroptosis via targeting of IREB2
(88)
miR-545
Inhibition of ferroptosis through inhibition of transferrin
(89)
lncRNA LINC00239
Inhibition of ferroptosis through interaction with Kelch-like ECH-related protein 1
(90)
SLC7A11, solute carrier family 7 member 11; GPX4, glutathione peroxidase 4; IREB2, iron-responsive element binding protein 2; miR, microRNA; CRC, colorectal cancer.
Attenuating chemotherapeutic resistance to oxaliplatin and 5-fluorouracil through ferroptosis in colorectal cancer.
A, Direct attenuation of chemotherapeutic resistance
Drug
Mechanism
(Refs.)
Oxaliplatin
Induction of ferroptosis through inhibition of the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway
(100)
Increased intracellular reactive oxygen species levels and promotion of ferroptosis through inhibition of cysteine desulfurase expression levels
(101)
B, Indirect attenuation of chemotherapeutic resistance
Drug
Mechanism
(Refs.)
Oxaliplatin
Promotion of ferroptosis through inhibition of RNA-binding motif single-stranded interacting protein 1 expression
(102)
Promotion of ferroptosis in Candida nucleatum
(103)
Promotion of ferroptosis through inhibition of cyclin-dependent kinase 1 expression
(104)
5-Fluorouracil
Promotion of ferroptosis through inhibition of lipid transport protein 2 expression
(82)
Promotion of ferroptosis through inhibition of serine protease 1 expression
(105)
KIF20A, kinesin family member 20A; NUAK1, NUAK family kinase 1; Nrf2, nuclear factor erythroid 2-related factor 2; GPX4, glutathione peroxidase 4.